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Abstract
Background: Inflammatory Bowel Diseases (IBD) remain significant health problems in the US and worldwide. IBD
is most often associated with eastern European ancestry, and is less frequently reported in other populations of
African origin e.g. African Americans (’AAs’). Whether AAs represent an important population with IBD in the US
remains unclear since few studies have investigated IBD in communities with a majority representation of AA
patients. The Louisiana State University Health Sciences Center in Shreveport (LSUHSC-S) is a tertiary care medical
center, with a patient base composed of 58% AA and 39% Caucasian (W), ideal for evaluating racial (AA vs. W) as
well and gender (M vs. F) influences on IBD.
Methods: In this retrospective study, we evaluated 951 visits to LSUHSC-S for IBD (between 2000 to 2008) using
non-identified patient information based on ICD-9 medical record coding (Crohn’s disease ‘CD’-555.0- 555.9 and
ulcerative colitis ‘UC’-556.0-556.9).
Results: Overall, there were more cases of CD seen than UC. UC and CD affected similar ratios of AA and
Caucasian males (M) and females (F) with a rank order of WF > WM > AAF > AAM. Interestingly, in CD, we found
that annual visits per person was the highest in AA M (10.7 ± 1.7); significantly higher (* -p < 0.05) than in WM (6.3
± 1.0). Further, in CD, the female to male (F: M) ratio in AA was significantly higher (*- p < 0.05) (1.9 ± 0.2) than in
Caucasians (F:M = 1.3 ± 0.1) suggesting a female dominance in AACD; no differences were seen in UC F: M ratios.
Conclusion: Although Caucasians still represent the greatest fraction of IBD (~64%), AAs with IBD made up >1/3
(36.4%) of annual IBD cases from 2000-2008 at LSUHSC-S. Further studies on genetic and environments risks for IBD
risk in AAs are needed to understand differences in presentation and progression in AAs and other ‘non-traditional’
populations.
Background
Crohn’s disease (CD) and ulcerative colitis (UC), the
major forms of inflammatory bowel disease (IBD), are
characterized clinically by diarrhea, weight loss and
fever as well as endoscopic, radiologic, histopathologic
findings and biochemical markers (e.g. perinuclear anti-
neutrophil cytoplasm (p-ANCA), anti-Saccharomyces
cerevisiae (ASCA) and IBD-specific p-ANCA markers)
[1]. The development of IBD is thought to depend on
several factors including genetic background,
environmental influences e.g. dietary “hygiene”, parasite
burden and subclinical infectious diseases [2-5]. These
factors lead to a complex overall distribution of IBD,
with some described patterns in disease prevalence. IBD
is considered a disease of developed nations especially
Northern Europe and the United States, usually of
colder climates with increased incidence as distance
from the equator increases [6-10]. IBD is now increas-
ingly reported in non-classical populations and in devel-
oping regions such as Asia, the Mid-East and in Africa
[11,12].
In a study of central-African (Ghana) black patients
[13] CD was viewed as a common, but often under-
diagnosed condition, while Zaahl et al. [14] have
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can blacks. In the US, IBD, (especially CD) is still
regarded as a syndrome affecting individuals of Eur-
opean descent, but there is increasing evidence for IBD
in the Hispanic and African American (AA) populations
[15].
It is possible that clinical features of IBD may differ in
AAs, leading to misdiagnosis and under-reporting of ‘min-
ority’ IBD [15]. Eidelwein et al. [16] reported that pediatric
CD was possibly more severe in AAs, often presenting
with lower body mass scores, blood sedimentation rates
and hemoglobin (Hb). AAs may also require more treat-
ment (e.g. steroids, anti-TNF-a) to manage their IBD. In a
study of pediatric/adolescent AA cases, White et al. [17],
found that AAs were older at the time of diagnosis/onset,
had a greater incidence of CD (>UC>indeterminate coli-
tis), and lower Hb. Conversely, a meta-analysis of 8 studies
with >2000 individuals suggested that no race-based differ-
ences exist in IBD susceptibility [18]. However, regional
studies may suggest differences in IBD in AA populations
exist. Ogunbi et al. report a CD incidence in AAs of
7-12 per 100,000 and 5-7 per 100,000 for UC [19]. In
African populations, Shapira and Tamir [20] suggested
that African CD incidence equals or exceeds that in
European-Americans, consistent with underestimates in
both African or AA IBD.
Incongruities about the incidence of IBD in AA popu-
lations may thus reflect low sampling, geographical
influences, variations in disease presentation, environ-
mental and socioeconomic factors that confound diag-
nosis and ultimately treatment. Gender-based
differences in IBD have also been reported [21]; the F:
M ratio in IBD may also be affected by urban/rural sta-
tus [22-24] and may be changing in recent years [25].
Sample Population of Shreveport/LSUHSC-S
One important limitation in this type of study is ade-
quate sampling, in this case, ideally selecting populations
in which AA patients at least match, or even exceed that
of Caucasians. Our study carried out at the LSU Health
Sciences Center in Shreveport (in accordance with
HIPAA regulations regarding privacy) should approxi-
mate local ethnic profiles in Shreveport,/Arkansas-
Louisiana-Texas region (’’Arklatex’’). The racial compo-
sition of Shreveport has been >50% AA since 2002 [26];
the self-identified ethnic background of patients at
LSUHSC-S (1999-2008) was 58.11% AA, and 39.42%
Caucasian, (plus 1.43% Hispanic and 1.04% Asian,
Native American plus other groups). Our goal was to
evaluate the proportion of IBD cases as related to race
and gender at LSUHSC-Shreveport, LA, a hospital ser-
ving the Northwest LA region with a roughly equal
racial (AA : W) ratio.
Methods
This study was reviewed and approved by the LSUHSC-
Shreveport Human Research Protection Program/Insti-
tutional Review Board (IRB). We used non-identified
ICD-9 codes (international statistical classification of
diseases) from information medical record codes for CD
(555.0 - 555.9) and UC (556.0 - 556.9). For every year in
the study, individual non-identified patients were evalu-
ated for self-identified race, gender and ICD-9 coding,
(each patient was counted only once annually). Ages of
individual patients at the time of annual visits were also
recorded. Cumulative cases of CD or UC visits per each
group were also counted (independent of the number of
patients). We then determined: 1) the annual number of
patients for each code, 2) the number of hospital visits
per group, 3) the age at visit for individual racial and 4)
gender populations at the LSUHSC in Shreveport, LA,
(between 2000 and 2008). Hospital visits per individual
were calculated as the total number of hospital visits
(separated by race and gender) for each specific condi-
tion (CD or UC) and dividing this number by the num-
ber of cases for each condition. One-way ANOVA
analysis was used to determine statistical significance
with Bonferroni Multiple Comparisons post-testing. Sta-
tistical significance between pairs of data was deter-
mined using unpaired student’st - t e s t .N o n l i n e a r
regression was used to calculate correlation and deter-
mine fit for trend lines in graphs. Because Hispanic,
Asian, and Native American populations constitute <1%
of total case reports for ICD-9 codes, these groups were
omitted from analysis; we compared Caucasian and Afri-
can-American populations with a further sub-grouping
for gender. Co-morbid conditions with CD and UC,
including diabetes (ICD-9 code 250.0), multiple sclerosis
(ICD-9 code 340), and arthritis, were also investigated.
Results
Data were collected on patients with CD and UC at
LSUHSC-S between 2000-8. The compiled data set
included: 1) the total number of annual visits, 2) the
annual number of cases, 3) the age at visit for each dis-
ease and 4) these factors separated both by genders and
by race at LSUHSC-S. Over the past 9 years, 665
patients with CD and 286 with UC treated at LSUHSC-
S were included in this study. Of CD patients, 428
(64.36%) were Caucasian, and 237 (35.64%) were Afri-
can-American. When the CD population was subdivided
by race and gender, 240 (36.09%) were Caucasian Fs,
188 (28.27%) were Caucasian M, 150 (22.56%) were AA
F, and 87 (13.08%) were AA M. Caucasians represented
63.99% (183) of UC patients, while African-Americans
comprised 36.01% (103) in this study. When UC
patients were subdivided by race and gender, 38.46%
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Page 2 of 8(110) were Caucasian F, 25.52% (73) were Caucasian M,
23.08% (66) were AA F, and 12.94% (37) were AA M
( F i g .1 ) .I ti si m p o r t a n tt op o i n to u tt h a tb e c a u s eo u r
study only examined unidentified hospital records, the
results only reflect institutional trends; and calculation
of true regional or geographical incidences would
require additional data on patient residence.
Average age at hospital visit
The average age (at hospital visit) for both CD and UC
was also studied. These data only reflect the average
patient age at hospital visit, and do not infer the age of
initial diagnosis. (CD: AA male 30.1 ± 1.73, A female 35
± 1.42, WM 31.28 ± 1.19, WF 34.67 ± 1.14); (UC: AAM
38.27 ± 3.7, AAF 39.7 ± 2.12, WM 38.7 ± 2, WF 41.4 ±
1.6 AVG., ± S.E.). There was no statistical significance
in average age amongst the population groups studied
within each respective disease. When comparing CD to
UC, at LSUHSC-Shreveport we did find that the average
age at time of visit for CD to be significantly lower than
for UC patients amongst Caucasian females (*, p < 0.05)
and Caucasian M (*, p < 0.05).
Number of cases per race/gender group
The annual number of cases per race/gender group was
also compared for each condition. In both CD and UC,
the average annual number of cases was highest
amongst Caucasian F followed by Caucasian M followed
by AA F, and finally the lowest number of cases was
seen amongst AA M. When comparing this data in CD,
Caucasian females had significantly more cases per year
than AA females (**, p < 0.01). This was also seen when
comparing Caucasian M to AAM (***, p < 0.001) (Fig.
2A). In UC, Caucasian F had significantly more cases
per year than Caucasian M (*, p < 0.05) and AA F (**, p
< 0.01). When comparing Caucasian M to AA M with
Figure 1 Percent distribution of CD and UC in Shreveport, LA (2000-8). There is a strikingly similar distribution in CD and UC gender and
race over a total of 9 years in Shreveport, LA. 665 CD patients and 286 UC patients were included in this study. There was variability and no
correlation when data analyzed annually.
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(Fig. 2B). Using the above-mentioned data, the average
annual visits per person were calculated by taking the
total number of visits per group yearly and dividing that
number by the number of cases per respective group.
Amongst Crohn’s disease patients, AA M made more
visits annually to LSUHSC-Shreveport than Caucasian
M with this disease (*, p < 0.05) (Fig. 3). Further analysis
for the trend of this disease was studied over 9 years for
each group.
Female: male ratios
At LSUHSC-Shreveport, IBD affected more Caucasian
(64%) than AA individuals (36%). We also compared the
ratios of gender and race for both CD and UC. When
comparing this ratio (W: B), men were affected more
than women in CD (**, p < 0.01) (Fig. 4A). In UC when
comparing the same ratio (W: B) between men and
women, no significant difference was found (Fig. 5A). In
both CD and UC women were more affected than men
among both races. When comparing the F: M ratio,
AAs were more affected than Caucasian (**, p < 0.01)
amongst CD patients (Fig. 4B), however comparing
the F: M ratio in UC, showed no significant difference
(Fig. 5B).
Discussion
IBD (Ulcerative Colitis, Crohn’s disease) has long been
considered as a group of diseases that affect primarily
Caucasian populations [18,27], an impression which has
recently been challenged by several studies. This
concept remains uncertain for several possible reasons
including under-sampling, racial or gender differences in
IBD presentation, geographical or socio-economic differ-
ences influencing IBD etiology. For example, lower
access to health care in AA could lead to under-report-
ing of IBD. Hospitalization for IBD is lower in AAs than
in Caucasians [28], issues related to health coverage and
reporting. Under-sampling in meta-analyses may also
minimize or underestimate important trends, leading to
erroneous conclusions regarding minority IBD incidence
Figure 2 Annual CD and UC cases by gender/racial group. In fig. 2A the average number of cases seen annually for Crohn’s disease is
greater amongst Caucasian females than AA females (**, p < 0.01), and is also greater amongst Caucasian M when compared to AA M (***, p <
0.001). In fig. 2B the average number of cases seen annually for UC is greater amongst Caucasian females than Caucasian M (*, p < 0.05),
Caucasian females than AA females (**, p < 0.01), and Caucasian M than AA M (*, p < 0.05). * Significantly different with p < 0.05; ** significantly
different with p < 0.01; *** significantly different with p < 0.001 using one-way ANOVA, Tukey-Kramer multiple comparison.
Figure 3 Annual Crohn’s Disease and Ulcerative Colitis visits
per person. AA males with Crohn’s Disease made more annual
visits to LSUHSC - Shreveport for treatment than Caucasian males
with the disease. * Significantly different with p < 0.05 using one-
way ANOVA, Bonferroni post-testing.
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Shreveport is unlikely. LSUHSC-Shreveport, part of the
“charity” system is a university teaching hospital, provid-
ing equal care to patients regardless of ability to pay.
We assume therefore that patient visits are not
restricted by economic considerations, and all patients
had equal access to health care. The ethnic/racial back-
ground at LSUHSC-S from 1999-2008 was 58.11% AA,
and 39.42% Caucasian, (with 1.43% Hispanic and 1.04%
Asian, Native American plus other groups). As of 2007,
the Shreveport population was 43% Caucasian and
53.6% African-American (US average = 74.1% Cauca-
sian, 12.4% = AA) [U.S. Census Bureau, 2005-2007
American Community Survey]. Between 2000-8, Cauca-
sians made up 64% of IBD cases, ~ 36% of IBD cases
were found in AAs [24].
Eidelwein et al. [16] also suggest differences may exist
for the presentation and management of CD in AA
Figure 4 Ratio comparison for Crohn’s disease between A) Caucasians: AAs and B) females: males. In fig. 4A, Crohn’sa f f e c t sm o r e
Caucasian than AA individuals (irrespective of genders). When comparing the W: B ratio, men were affected more than women (**, p < 0.01). In
fig. 4B, Crohn’s was seen to affect more women than men amongst both races. When comparing this ratio (F: M), AA individuals are affected
more than Caucasian (**, p < 0.01). Results were compared using two-tailed unpaired student t-test.
Figure 5 Ratio comparisons for Ulcerative Colitis between A) Caucasians: AAs and B) females: males.I nf i g .5 A ,U Ca f f e c t sm o r e
Caucasian than AA individuals (irrespective of gender). When comparing this ratio (W: B) between men and women, no significance is seen. In
fig. 5B, UC affects more women than men (irrespective of race). When comparing this ratio (F: M) between Caucasian and AA individuals, no
significant difference is seen. Results were compared using two-tailed unpaired student t-test.
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mentation rate, low body mass z-score and [Hb], evi-
dence of stricturing and a greater need for steroids and
Infliximab to control disease). If IBD does emerge earlier
in AA vs. Caucasians [32], it may be more aggressive
[33]. With respect to other populations, Hispanics may
have higher rates of UC (including co-morbid evidence
of arthritis/uveitis) [34]. In UC, Hirschsprungs’ disease
(CPC 751.3) and schizophrenia (CPC 295) have been
considered as co-morbid conditions. In CD, osteoporosis
(CPC 733.0-.2) and amyloidosis (CPC 277) have also
been reported [35]. IBD co-morbid conditions suggest
that IBD may be systemic and polygenic, affecting
numerous extra-intestinal targets [35], and that devia-
tions from ‘classical’ (Caucasian)’ IBD presentation
might reflect race-based gene polymorphisms or envir-
onmental cues. All of these conditions as well as dia-
betes (CPC 250.0), multiple sclerosis (CPC340), and
arthritis (CPC 714,715) were all investigated, but yielded
too few co-morbid cases (<1%) for analysis based on
patient records. Further studies are still required.
Several genes linked with development of IBD, have
been compared in AA and Caucasian populations. In
IBD, polymorphisms in Caspase recruitment domain-15
‘CARD15’ may dysregulate intestinal epithelial apoptosis
and barrier [36]. Kugathasan et al. [37] correlated gene
frequencies with racial background in IBD, finding fewer
AA CARD15 mutations. Several CARD15 polymorph-
isms exist: CARD15 (2936insC) may mediate responses
t oL P Si nA AC D[ 3 8 ] .A d d i t i o n a l‘non-classical’
CARD15 mutations e.g. A661P may drive AA CD, while
the A725G CARD15 polymorphism may influence AA
UC [39].
A n o t h e rr i s kf a c t o rf o rC Di st h eN O D 2g e n e
(Nucleotide-binding oligomerization domain containing
2). 3 polymorphisms in the NOD2/CARD15 gene
(R702W, G908R and Leu1007finsC) (16q12) are risk fac-
tors for CD [40] by altering NF-kB influence over intest-
inal immune responses [30]. NOD2 polymorphisms are
associated with ileal CD in Caucasians; in AA NOD2
may promote small bowel involvement, earlier onset,
and fibro-stenotic disease uveitis and sacroiliitis [30].
Stenson and Snapper [41] cite several factors con-
founding accurate diagnosis of UC vs. CD including lack
of standard criteria for diagnosis, inconsistent case his-
tories, misdiagnosis, and misclassification. It is uncertain
whether and how IBD disease activity is more severe in
AAs. Many different approaches have been used to
quantify IBD activity, but there is still no universally
accepted scale of IBD severity. The Crohn’s disease
activity index (CDAI) provides a means of evaluating
CD by assigning scores to subjective IBD measures
(stool #, bleeding, and pain). Other studies use fistulae,
extra-intestinal manifestations, surgical requirements
and frequency of hospitalization as ‘surrogate’ markers
of IBD. A scale for UC severity, using the extent of
proximal colon involvement and clinical are also
described [42-44].
It is noteworthy that the annual number of visits to
LSUHSC for IBD was highest in AA males, (higher than
Caucasian males) and may represent a significant ‘surro-
gate’ marker of disease, (similar to frequency of hospita-
lization). In our study between 2000-2008, the
Caucasian: African-American patient ratio was 0.67:1.
A tt h es a m et i m ew ef o u n dt h a tm o r et h a n1 / 3o fI B D
cases (35.64%) were seen in African-Americans, vs.
64.36% of IBD cases who were Caucasian (W). The Cau-
casian: African American IBD ratio is 1.8:1. Based on
the ratios from our center, Caucasians were 2.68 times
more likely to develop a form of IBD. We found a
greater proportion of female cases in both CD and in
UC with a male: female ratio of (0.7 ± 0.05, avg., ±
SEM) in CD and a male: female ratio of (0.63 ± 0.07,
avg. ± s.e.m.) in UC. This ratio is reversed from that
reported by Kugathasan et al. [45] who reported male :
female ratios in CD of 1.6, and in UC of 1.2 (predomi-
nantly a male disease) in pediatric populations. Kappel-
man et al. in a prevalence study of 9 million Americans
found CD to be more prevalent among females (216
cases/100,000) than males (183 cases/100,000); that
study found no significant difference in UC in adult
populations [46]. Our data on gender in IBD are consis-
tent with findings in Kappelmans’ study regarding CD,
but ours differ from their data on UC. Reasons for a
female dominance in UC and CD in this study are not
clear, but could reflect geographic or socio-economic
factors.
Among UC patients at LSUHSC, 286 patients were
seen over 9 years. Of these, 63.99% (n = 183) were Cau-
casian; of these, 38.46% (n = 110) were female and 73
(25.52%) were male. African-Americans comprised
36.01% (n = 103) of UC patients; of these 23.08% (n =
66) were female and 12.94% (n = 37) were male (Fig. 1).
This means there are 2.33 times more CD than UC
patients seen at the LSUHSC-Shreveport. Kappelman et
al. [46] found a greater prevalence of UC (238 cases/
100,000) over CD (201 cases/100,000), we found fewer
UC cases than CD.
We found striking similarities in the fractional distri-
butions between different populations of CD and UC
patients included in the entirety of our study. In Crohn’s
disease, WF were 36.09%, WM were 28.27%, BF were
22.56%, and BM were 13.08%. In ulcerative colitis, WF
were 38.46%, WM were 25.52%, BF were 23.08%, and
BM were 12.94%. (There were no remarkable year-to-
year differences between these groups).
Although the number of hospital visits at the
LSUHSC-Shreveport for CD and UC have been
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have also increased, and the fraction of cases for each
condition has not changed significantly. Our results
among these groups show that AA M had more hospital
visits (per individual) for CD than other groups; this was
not found when analyzing UC visits (Fig. 3). AA females
had the 2
nd highest rate of hospital visits (per individual)
for CD, (not significantly different vs. WF). While preli-
minary, hospital visits may represent a potential ‘surro-
gate’ marker of disease activity requiring additional
study.
Conclusions
In summary, we provide racial, gender and age statistics
of IBD at the LSUHSC in Shreveport over the past 9
years. Our institution serves more AAs than any other
racial group and provides an important site for opportu-
nity to study IBD in African Americans. While Cauca-
sians represented the most cases of IBD, AAs
represented 36% of IBD cases with the highest annual
visits among AA males. Classical assumptions about the
prevalence and course of IBD in AAs may underlie the
failure to suspect, diagnose, and treat IBD in this
population.
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